Together with clinical researchers at the medical capus, but also other international collaborators, we aim to identify patients at risk for hyperinflammatory immune diseases, which can lead to severe life-threatening complications during hospitalization or prevent a fast recovery from routine surgeries.
We are involved in several local and international clinical trials, which focus on the pathogenesis of the systemic inflammatory response syndrome (SIRS), vascular diseases, myelodysplastic syndrome (MDS), and colon cancer. In the past we contributed to research projects focusing on pre-term birth and age-related macula degeneration (AMD).
Our scientific mission is to identify people with a hyperinflammatory immune system using an in-vitro whole blood immune activation assay, which uses various immune triggers to induce inflammatory responses. Utilizing RNA-sequencing techniques and multiplexing assays for classical cytokines present in the blood, we are able to quantify bioinformatically the immune activation status of each patient and are able to predict if the patient is at risk to develop severe complications based on a systemic activation of the immune system, which could be prevented by the administration of anti-inflammatory drugs.